Hansoh Pharmaceutical Group Company Limited announced that on April 24, 2024, Hansoh (Shanghai) Healthtech Company Limited (Han Sen (Shang Hai)Jian Kang Ke Ji You Xian Gong Si) (the "Licensee"), a wholly-owned subsidiary of the Company, entered into a license agreement (the " Licensing Agreement") with Qyuns Therapeutics Co. Ltd. Pursuant to the Licensing Agreement, the Licensee obtained an exclusive license from Qyuns to develop and commercialize Monoclonal Antibody QX004N ("QX004N") within China (including Hong Kong, Macau and Taiwan). The Licensee will be responsible for the research and development ("R&D"), manufacturing and commercialization of QX004N in all developable dosage forms and indications in China, and will pay an upfront payment of RMB 75 million and potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB 1,032 million, plus tiered royalties on future product sales.